BioLineRx (BLRX) vs Scienture (SCNX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
BioLineRx is the larger company by market cap ($4.8 million vs $4.1 million), about 1.2 times the size, while Scienture is growing revenue faster (+215.9% vs -95.9%). BioLineRx converts more of its revenue into profit, with a net margin of -171.7% versus -9618.0%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BLRX | SCNX |
|---|---|---|
| Share price | $0.9639 | $2.28 |
| Market cap | $4.80M | $4.07M |
| 1-day change | -8.20% | -6.45% |
| YTD return | -65.20% | — |
| 1-year return | -70.34% | — |
| 5-year return | -99.07% | — |
| EPS (TTM) | $0.00 | $-51.70 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $1.18M | $431.61K |
| Revenue growth (YoY) | -95.92% | +215.87% |
| Net income (latest FY) | $-2.03M | $-41.51M |
| Gross margin | 80.51% | 76.80% |
| Operating margin | -871.78% | -9867.92% |
| Net margin | -171.69% | -9618.03% |
| 52-week high | $3.95 | $18.75 |
| 52-week low | $0.78 | $2.00 |
| Distance from 52-week high | -75.60% | -87.85% |
| Analyst consensus | none | buy |
| Avg. price target upside | +2182.39% | +1546.25% |
| Average volume | 23.43K | 156.51K |
| Shares outstanding | 4.98M | 1.79M |
| Employees | 20 | 4 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- BioLineRx is more profitable, keeping -171.7 cents of every revenue dollar as net income versus -9618.0 cents for Scienture.
- Scienture grew revenue faster in its latest fiscal year (+215.87% vs -95.92%).
About BioLineRx
BLRX stock →BioLineRx Ltd., a biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes GLIX1, an oral, small molecule targeting DNA damage response in glioblastoma and other cancers; and APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma.
Health Care · Biotechnology: Pharmaceutical Preparations · 20 employees
About Scienture
SCNX stock →Scienture Holdings, Inc. operates as pharmaceutical company that focuses on development and commercialization of products for the treatment of central nervous system and cardiovascular diseases in the United States.
Health Care · Biotechnology: Pharmaceutical Preparations · 4 employees
BLRX vs SCNX FAQ
Which is bigger, BioLineRx or Scienture?
BioLineRx (BLRX) is larger, with a market capitalization of $4.80M compared with $4.07M for Scienture (SCNX).
Are BioLineRx and Scienture in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.